Shares of Geron Corp. (NASDAQ:GERN) have been given a consensus rating of “Hold” by the seven brokerages that are currently covering the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $5.50.

A number of analysts recently commented on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $5.00 price target (down previously from $10.00) on shares of Geron Corp. in a research note on Tuesday, September 13th. BTIG Research reaffirmed a “neutral” rating on shares of Geron Corp. in a research note on Monday, September 12th. FBR & Co reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Geron Corp. in a research note on Thursday, September 22nd. Finally, Zacks Investment Research lowered Geron Corp. from a “buy” rating to a “hold” rating in a research note on Monday, November 14th.

Several institutional investors have recently modified their holdings of GERN. Commonwealth Equity Services Inc increased its position in shares of Geron Corp. by 0.3% in the second quarter. Commonwealth Equity Services Inc now owns 73,397 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 200 shares during the last quarter. Rhumbline Advisers increased its position in shares of Geron Corp. by 0.5% in the second quarter. Rhumbline Advisers now owns 156,877 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 840 shares during the last quarter. Creative Planning increased its position in shares of Geron Corp. by 3.5% in the second quarter. Creative Planning now owns 59,700 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,000 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Geron Corp. by 0.7% in the third quarter. California State Teachers Retirement System now owns 318,794 shares of the biopharmaceutical company’s stock valued at $720,000 after buying an additional 2,200 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Geron Corp. by 4.0% in the third quarter. Morgan Stanley now owns 59,967 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,313 shares during the last quarter. Hedge funds and other institutional investors own 38.44% of the company’s stock.

Shares of Geron Corp. (NASDAQ:GERN) opened at 2.19 on Tuesday. Geron Corp. has a 1-year low of $1.81 and a 1-year high of $5.30. The firm’s market capitalization is $348.53 million. The stock has a 50 day moving average of $2.12 and a 200-day moving average of $2.52.

Geron Corp. (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04. Geron Corp. had a negative return on equity of 21.96% and a negative net margin of 469.51%. The company earned $5.10 million during the quarter, compared to analyst estimates of $0.22 million. During the same quarter last year, the firm posted $0.17 earnings per share. The firm’s revenue was down 85.6% on a year-over-year basis. On average, equities analysts expect that Geron Corp. will post ($0.19) earnings per share for the current year.

WARNING: “Geron Corp. (GERN) Receives $5.50 Consensus Target Price from Analysts” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of US and international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2016/11/25/geron-corp-gern-receives-5-50-consensus-target-price-from-analysts.html.

Geron Corp. Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

5 Day Chart for NASDAQ:GERN

Receive News & Stock Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related stocks with our FREE daily email newsletter.